Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

ABLYNX ANNOUNCES WARRANT EXERCISE


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-01-21 18:02:04 -

REGULATED INFORMATION


GHENT,  Belgium,  21 January  2013 -  Ablynx  [Euronext  Brussels:  ABLX]  today
announced,  in conformity with Title  II of the Law  of 2 May 2007 and the Royal
Decree  of 14 February 2008, that  an additional 61,812 common  shares have been
issued  by the Company in exchange for €329,619.51 as the result of the exercise
of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 43,779,197 shares outstanding.

About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and 
pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com. For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t:   +32 (0)9 262 00 07 m: +44 (0)7771 954 193 /      +32 (0)473 39 50 68 e:  edwin.moses@ablynx.com Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX M:Communications: Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t:   +44 207 920 2330 e:  ablynx@mcomgroup.com press release in pdf format: hugin.info/137912/R/1671922/543522.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Ablynx via Thomson Reuters ONE [HUG#1671922]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com